Insights on prospects of nano-siRNA based approaches in treatment of Cancer

Goyal, R; Chopra, H; singh, I; Dua, K; Gautam, RK

Insights on prospects of nano-siRNA based approaches in treatment of Cancer

Goyal, R Chopra, H singh, I Dua, K

Gautam, RK

Permalink

Publisher:: Frontiers Media SA
Publication Type:: Journal Article
Citation:: Frontiers in Pharmacology, 13

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.39 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Goyal, R
dc.contributor.author	Chopra, H
dc.contributor.author	singh, I
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Gautam, RK
dc.date.accessioned	2022-08-25T13:04:26Z
dc.date.available	2022-08-25T13:04:26Z
dc.identifier.citation	Frontiers in Pharmacology, 13
dc.identifier.issn	1663-9812
dc.identifier.uri	http://hdl.handle.net/10453/160868
dc.description.abstract	<jats:p>siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications.</jats:p>
dc.language	en
dc.publisher	Frontiers Media SA
dc.relation.ispartof	Frontiers in Pharmacology
dc.relation.isbasedon	10.3389/fphar.2022.985670
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.title	Insights on prospects of nano-siRNA based approaches in treatment of Cancer
dc.type	Journal Article
utslib.citation.volume	13
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	open_access	*
dc.date.updated	2022-08-25T13:04:24Z
pubs.publication-status	Published online
pubs.volume	13

Abstract:

siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160868